GT200100147A - IMIDAZOL DERIVATIVES - Google Patents

IMIDAZOL DERIVATIVES

Info

Publication number
GT200100147A
GT200100147A GT200100147A GT200100147A GT200100147A GT 200100147 A GT200100147 A GT 200100147A GT 200100147 A GT200100147 A GT 200100147A GT 200100147 A GT200100147 A GT 200100147A GT 200100147 A GT200100147 A GT 200100147A
Authority
GT
Guatemala
Prior art keywords
compounds
affections
synthesis
pharmaceutical compositions
bed
Prior art date
Application number
GT200100147A
Other languages
Spanish (es)
Inventor
Michael Kirk Ahlijanian
Christopher Blair Cooper
Christopher John Helal
Lit-Fui Lau
Frank Samuel Menniti
Mark Allen Sanner
Patricia Ann Seymour
Anabella Villalobos
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT200100147A publication Critical patent/GT200100147A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA (I), EN DONDE R1, R2, R3, R4 SON GRUPOS FUNCIONALES DECRITOS EN EL EXPEDIENTE. TAMBIEN SE REFIERE A SU SALES FARMACEUTICAMENTE ACEPTABLES, COMPOSICIONES FARMACEUTICAS DE DICHOS COMPUESTOS. ESTOS COMPUESTOS SON UTILES PARA TRATAR Y PREVENIR ENFERMEDADES Y AFECCIONES QUE COMPRENDEN UN CRECIMIENTO CELULAR ANORMAL, TAL COMO EL CANCER, ENFERMEDADES Y AFECCIONES NEURODEGENERATIVAS, Y LAS AFECTADAS POR NEUROTRASMISION DE DOPAMINA. TAMBIEN SE DESCRIBEN COMPOSICIONES FARMACEUTICAS Y PROCEDIMIENTOS PARA TRATAR LA FERTILIDAD MASCULINA, Y MOTILIDAD DE ESPERMATOZOIDES, DIABETES MELLITUS, DISMINUCION DE LA TOLERANCIA A LA GLUCOSA, SINDROME METABOLICO O SINDROME X, SINDORME DE OVARIOS POLIQUISTICOS, ADIPOGENESIS Y OBESIDAD; MIOGENESIS Y DEBILIDAD, POR EJEMPLO LA REDUCCION DEL RENDIMIENTO FISICO RELACIONADA CON LA EDAD, SACOPENIA AGUDA, POR EJEMPLO ATROFIA MUSCULAR, Y/O CAQUEXIA ASOCIADA A QUEMADURAS, REPOSO EN CAMA, ETC.THE PRESENT INVENTION REFERS TO COMPOUNDS OF FORMULA (I), WHERE R1, R2, R3, R4 ARE FUNCTIONAL GROUPS DESCRIBED IN THE RECORD. IT ALSO REFERS TO ITS PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITIONS OF SUCH COMPOUNDS. THESE COMPOUNDS ARE USEFUL TO TREAT AND PREVENT DISEASES AND AFFECTIONS THAT INCLUDE ABNORMAL CELLULAR GROWTH, SUCH AS CANCER, NEURODEGENERATIVE DISEASES AND AFFECTIONS, AND THOSE AFFECTED BY DOPAMINE NEUROTRASMISSION. PHARMACEUTICAL COMPOSITIONS AND PROCEDURES ARE ALSO DESCRIBED TO TREAT MALE FERTILITY, AND MOTIVITY OF SpermATOZOIDS, MELLITUS DIABETES, GLUCOSE TOLERANCE, METABOLIC SYNDROME OR SYMPOSIS, SYNTHESIS ORYSIS, SYNTHESIS, OBJECTIVES; MIOGENESIS AND WEAKNESS, FOR EXAMPLE THE REDUCTION OF AGE-RELATED PHYSICAL PERFORMANCE, ACUTE SACOPENIA, FOR EXAMPLE MUSCULAR ATROPHY, AND / OR BURNING ASSOCIATED BED, BED, ETC.

GT200100147A 2000-07-31 2001-07-23 IMIDAZOL DERIVATIVES GT200100147A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22172400P 2000-07-31 2000-07-31

Publications (1)

Publication Number Publication Date
GT200100147A true GT200100147A (en) 2002-06-25

Family

ID=22829075

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200100147A GT200100147A (en) 2000-07-31 2001-07-23 IMIDAZOL DERIVATIVES

Country Status (35)

Country Link
EP (1) EP1305295A1 (en)
JP (2) JP4166084B2 (en)
KR (1) KR20030019644A (en)
CN (1) CN1444567A (en)
AP (1) AP2001002232A0 (en)
AR (1) AR032629A1 (en)
AU (1) AU2001270944A1 (en)
BG (1) BG107469A (en)
BR (1) BR0112862A (en)
CA (1) CA2418115A1 (en)
CR (1) CR6861A (en)
CZ (1) CZ2003225A3 (en)
DO (1) DOP2001000220A (en)
EA (1) EA200300097A1 (en)
EC (1) ECSP034445A (en)
EE (1) EE200300049A (en)
GT (1) GT200100147A (en)
HR (1) HRP20030048A2 (en)
HU (1) HUP0303069A3 (en)
IL (1) IL153787A0 (en)
IS (1) IS6662A (en)
MA (1) MA26932A1 (en)
MX (1) MXPA03000939A (en)
NO (1) NO20030472L (en)
NZ (1) NZ523272A (en)
OA (1) OA12345A (en)
PA (1) PA8523701A1 (en)
PE (1) PE20020337A1 (en)
PL (1) PL365134A1 (en)
SK (1) SK1042003A3 (en)
SV (1) SV2002000571A (en)
TN (1) TNSN01114A1 (en)
UY (1) UY26862A1 (en)
WO (1) WO2002010141A1 (en)
ZA (1) ZA200300819B (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007832A (en) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aryl ureas with angiogenesis inhibiting activity.
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
JP4662764B2 (en) 2002-06-14 2011-03-30 メルク セローノ ソシエテ アノニム Azol methylidene cyanide derivatives and their use as protein kinase modulators
DE10233817A1 (en) * 2002-07-25 2004-02-12 Aventis Pharma Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
US7141561B2 (en) 2002-07-25 2006-11-28 Sanofi-Aventis Deutschland Gmbh Substituted diaryl heterocycles, process for their preparation and their use as medicaments
GB0308968D0 (en) * 2003-04-17 2003-05-28 Glaxo Group Ltd Medicaments
CA2526617C (en) 2003-05-20 2015-04-28 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
UA84156C2 (en) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CN1934091B (en) * 2004-03-23 2012-02-08 辉瑞产品公司 imidazole compounds for the treatment of neurodegenerative disorders
EP1751139B1 (en) 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
RU2399614C2 (en) 2004-09-21 2010-09-20 Астеллас Фарма Инк. Amino alcohol derivatives
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
BRPI0616141A2 (en) * 2005-09-22 2011-06-07 Pfizer Prod Inc imidazole compounds for the treatment of neurological disorders
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
BRPI0706621A2 (en) 2006-01-18 2011-04-05 Amgen Inc compound, pharmaceutical composition, methods for treating a kinase-mediated disorder in a mammal and for treating a proliferation-related disorder in a mammal, and, use of the compound
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090071662A (en) 2006-10-21 2009-07-01 애보트 게엠베하 운트 콤파니 카게 Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
JP5756011B2 (en) * 2008-04-24 2015-07-29 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 1- (7- (Hexahydropyrrolo [3,4-C] pyrrol-2 (1H) -yl) quinolin-4-yl) -3- (pyrazine-2) as glycogen synthase kinase 3 (GSK-3) -Yl) urea derivatives and related compounds
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
RU2666730C2 (en) 2012-12-07 2018-09-12 Кемосентрикс, Инк. Diazole lactams
CN104918921B (en) 2012-12-21 2017-09-22 凯莫森特里克斯股份有限公司 Diazole acid amides
US10653672B2 (en) 2014-02-07 2020-05-19 National University Corporation Tokyo Medical And Dental University Myogenesis promotor, muscle atrophy inhibitor, medical composition and TAZ activator
EP3662919A1 (en) 2015-08-31 2020-06-10 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
GB201605126D0 (en) 2016-03-24 2016-05-11 Univ Nottingham Inhibitors and their uses
JP2019510832A (en) 2016-04-07 2019-04-18 ケモセントリクス，インコーポレーテッド Reduction of tumor burden by administering a CCR1 antagonist in combination with a PD-1 inhibitor or PD-L1 inhibitor
CN107698567B (en) * 2017-10-25 2020-09-15 西南大学 Isatin azole alcohol compound and preparation method and medical application thereof
EP3920885A1 (en) 2019-02-08 2021-12-15 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
GB201908424D0 (en) * 2019-06-12 2019-07-24 Imp College Innovations Ltd Novel compounds
US10590087B1 (en) 2019-08-09 2020-03-17 Pfizer Inc. Solid state forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide and uses thereof
US11884634B2 (en) 2019-08-09 2024-01-30 Pfizer Inc. Compositions of solid forms of (S)-2-(((S)-6,8-difluoro-1,2,3,4- tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide
CN112250636A (en) * 2020-11-09 2021-01-22 广西科技大学 5-aminoimidazole compound and synthesis method thereof
US11504354B1 (en) 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401851A (en) * 1992-06-03 1995-03-28 Eli Lilly And Company Angiotensin II antagonists
US5760246A (en) * 1996-12-17 1998-06-02 Biller; Scott A. Conformationally restricted aromatic inhibitors of microsomal triglyceride transfer protein and method
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
ZA987383B (en) * 1997-08-19 2000-02-17 Lilly Co Eli Treatment of congestive heart failure with growth hormone secretagogues.
DE69919707T2 (en) * 1998-06-19 2005-09-01 Chiron Corp., Emeryville GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
WO2000021550A2 (en) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methods and compositions for treating neurodegenerative diseases
CO5160260A1 (en) * 1999-02-19 2002-05-30 Lilly Co Eli SECRETAGOGOS OF THE HORMONE OF GROWTH DERIVED FROM IMI- DAZOL 1,4- SUBSTITUTED
EP1106180B1 (en) * 1999-12-08 2003-11-12 Centre National de la Recherche Scientifique (CNRS) Use of hymenialdisine or derivatives thereof in the manufacture of medicaments

Also Published As

Publication number Publication date
PL365134A1 (en) 2004-12-27
PE20020337A1 (en) 2002-05-08
NO20030472D0 (en) 2003-01-30
SV2002000571A (en) 2002-10-24
NZ523272A (en) 2004-08-27
CA2418115A1 (en) 2002-02-07
OA12345A (en) 2004-04-13
WO2002010141A1 (en) 2002-02-07
NO20030472L (en) 2003-03-27
HUP0303069A2 (en) 2004-03-01
SK1042003A3 (en) 2004-05-04
AU2001270944A1 (en) 2002-02-13
CN1444567A (en) 2003-09-24
PA8523701A1 (en) 2002-04-25
MA26932A1 (en) 2004-12-20
EE200300049A (en) 2004-10-15
JP2004505111A (en) 2004-02-19
IL153787A0 (en) 2003-07-31
BG107469A (en) 2003-09-30
DOP2001000220A (en) 2002-05-15
MXPA03000939A (en) 2003-06-24
BR0112862A (en) 2003-07-01
KR20030019644A (en) 2003-03-06
CR6861A (en) 2004-03-11
EA200300097A1 (en) 2003-06-26
JP4166084B2 (en) 2008-10-15
HRP20030048A2 (en) 2003-04-30
EP1305295A1 (en) 2003-05-02
IS6662A (en) 2002-12-19
ZA200300819B (en) 2004-04-20
HUP0303069A3 (en) 2004-04-28
TNSN01114A1 (en) 2005-11-10
ECSP034445A (en) 2003-03-10
AR032629A1 (en) 2003-11-19
UY26862A1 (en) 2002-02-28
AP2001002232A0 (en) 2001-09-30
CZ2003225A3 (en) 2004-02-18
JP2008255123A (en) 2008-10-23

Similar Documents

Publication Publication Date Title
GT200100147A (en) IMIDAZOL DERIVATIVES
GT200100179A (en) DERIVATIVES OF PIRAZOL.
CR8147A (en) PIRIDO DERIVATIVES 2, 1A-ISOQUINOLINE, AS DPP-IV INHIBITORS
PA8566101A1 (en) NEW DERIVATIVES OF PIRIDINA AND PIRIMIDINA
PA8566201A1 (en) NEW DERIVATIVES OF PIRIDINA AND QUINOLINA
UY27518A1 (en) NEW PIRROLIDINE DERIVATIVES
CL2008001922A1 (en) Compounds derived from benzimidazol-2-piperidine, inhibitors of the signaling pathway of hedgehog proteins; pharmaceutical composition comprising one of the compounds; and use of the compounds in the preparation of medicaments useful in the treatment of abnormal cell growth conditions, such as cancer.
MY149622A (en) Pyrazoles as 11-beta-hsd-1
WO2007128480A3 (en) Thioglycosides as pharmaceutically active agents
PA8580301A1 (en) NEW BENZOIMIDAZOL DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS
PA8562801A1 (en) NEW DERIVATIVES OF PIRIDO (2,1-A) ISOQUINOLINA
MX2007010532A (en) 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus.
AR053412A1 (en) INHIBITING COMPOUNDS OF INTERACTION BETWEEN MDM2 AND P53, A METHOD OF PREPARATION, PHARMACEUTICAL COMPOSITION AND USE OF THE COMPOUND TO MANUFACTURE MEDICATIONS
GT200300296A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
AR077415A2 (en) DERIVATIVES OF REPLACED OXINDOL, MEDICATIONS THAT UNDERSTAND AND USE THEMSELVES
PA8551001A1 (en) NEW COMPOUNDS
CR7743A (en) NEW OXAZOL AND TIAZOL COMPOUNDS AS INHIBITOR OF THE TRANSFORMING GROWTH FACTOR (TGF)
ATE430743T1 (en) BENZIMIDAZOLE SUBSTITUTED THIOPHENE DERIVATIVES ACTING ON IKK3
CO4810375A1 (en) DERIVATIVES OF 9-AMINO-3-KETO Erythromycin
TW200517389A (en) Biaryloxymethylarenecarboxylic acids
AR020032A1 (en) DERIVATIVES OF 1,3-METHYL Erythromycin.
CO6210702A2 (en) PIRAZOLOPIRIMIDINE DERIVATIVE
BRPI0407968A (en) oxamide derivatives useful as raf kinase inhibitors
PA8592801A1 (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
EA200870223A1 (en) DERIVATIVES OF BENZOIZOINDOL FOR THE TREATMENT OF PAIN